Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 325
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Rev Neurol (Paris) ; 178(6): 609-615, 2022 Jun.
Article in English | MEDLINE | ID: mdl-34801264

ABSTRACT

OBJECTIVE: To evaluate the efficiency of resective epilepsy surgery (RES) in patients over 50 years and determine prognostic factors. RESULTS: Over the 147 patients over 50 years (54.9±3.8 years [50-69]) coming from 8 specialized French centres for epilepsy surgery, 72.1%, patients were seizure-free and 91.2% had a good outcome 12 months after RES. Seizure freedom was not associated with the age at surgery or duration of epilepsy. In multivariate analysis, seizure freedom was associated with MRI and neuropathological hippocampal sclerosis (HS) (P=0.009 and P=0.028 respectively), PET hypometabolism (P=0.013), temporal epilepsy (P=0.01). On the contrary, the need for intracranial exploration was associated with a poorer prognosis (P=0.001). Postoperative number of antiepileptic drugs was significantly lower in the seizure-free group (P=0.001). Neurological adverse event rate after surgery was 21.1% and 11.7% of patients had neuropsychological adverse effects overall transient. CONCLUSIONS: RES is effective procedure in the elderly. Even safe it remains at higher risk of complication and population should be carefully selected. Nevertheless, age should not be considered as a limiting factor, especially when good prognostic factors are identified.


Subject(s)
Epilepsy, Temporal Lobe , Epilepsy , Aged , Anticonvulsants/therapeutic use , Electroencephalography/methods , Epilepsy/complications , Epilepsy, Temporal Lobe/complications , Humans , Magnetic Resonance Imaging , Retrospective Studies , Seizures/epidemiology , Seizures/etiology , Seizures/surgery , Treatment Outcome
2.
Rev Epidemiol Sante Publique ; 65(2): 137-148, 2017 Apr.
Article in French | MEDLINE | ID: mdl-28245953

ABSTRACT

BACKGROUND: In France, chronic diseases affect 3 million children. In children with chronic conditions, long-term somatic outcome has been well described, but little is known about the psychosocial aspects of well-being. METHODS: Our aim was to build a self-administered questionnaire of global well-being in adults who had a chronic disease since or during childhood using a multidimensional and nonspecific approach. The questionnaire was constructed by a multidisciplinary group (epidemiologists, clinicians, sociologist, statistician). Items were built in compliance with reference data from the French general population (national surveys, free access) to allow comparative analysis adjusted for age and sex (and eventually other confounding factors) by indirect standardization (qualitative variables) or Z-scores (quantitative variables). RESULTS: The GEDEPAC-2 includes 108 items exploring 11 domains: education, employment, housing, material security, social links, civic engagement, leisure, environment, physical health/risky behavior, health-related quality of life and sex life. Factual questions and satisfaction scales jointly explore social well-being. Quality of life is analyzed in terms of physical quality of life, mental quality of life, fatigue and burden of treatment by 3 questionnaires validated in French (SF-12; MFI-20; Burden of Treatment Questionnaire). Experience of transition from pediatric to adult healthcare is described in 21 items. Paper and electronic versions were developed. CONCLUSION: Built in a multidimensional approach to well-being and in line with the available reference data, GEDEPAC-2 will facilitate the implementation of future studies on impact in adulthood of chronic disease in childhood.


Subject(s)
Chronic Disease/epidemiology , Chronic Disease/psychology , Quality of Life , Transition to Adult Care , Adolescent , Adult , Age of Onset , Child , Child Welfare , Employment , Female , France/epidemiology , Humans , Male , Self Concept , Surveys and Questionnaires , Transition to Adult Care/standards , Transition to Adult Care/statistics & numerical data , Young Adult
3.
Diabetologia ; 53(5): 907-13, 2010 May.
Article in English | MEDLINE | ID: mdl-20111856

ABSTRACT

AIMS/HYPOTHESIS: Insulin resistance (IR) and the metabolic syndrome (MS) have been reported in adults as a consequence of being born small for gestational age (SGA). The process seems to be initiated early in life; however, little is known about the progression of MS and IR in young adults. We hypothesised that being born SGA would promote a greater progression over time of IR and MS, reflecting not only the gain in weight and fat mass but also the extension of the fetal programming process. METHODS: Participants were selected from a community-based cohort and born full-term either SGA (birthweight <10th percentile) or appropriate for gestational age (25th < birthweight < 75th percentile). A total of 1,308 individuals were prospectively followed between the ages of 22 and 30 years. RESULTS: At both ages, individuals born SGA were more insulin-resistant and showed a significantly higher prevalence of MS. Over the 8 year follow-up, the risk of developing MS was twofold higher in those SGA, after adjustment for gain in BMI, whereas the progression of IR was not significantly affected by the birth status. CONCLUSIONS/INTERPRETATION: Our data suggest that metabolic disorders in SGA individuals are amplified by the weight gain with time when adults, both probably resulting from fetal programming. Moreover, the modest increase in IR contrasts with the constant and much higher prevalence of MS.


Subject(s)
Fetal Development/physiology , Infant, Small for Gestational Age/metabolism , Insulin Resistance/physiology , Metabolic Syndrome/epidemiology , Metabolic Syndrome/metabolism , Weight Gain/physiology , Adult , Body Composition/physiology , Body Mass Index , Case-Control Studies , Chi-Square Distribution , Female , Humans , Infant, Newborn , Lipids/blood , Longitudinal Studies , Male , Prevalence , Regression Analysis , Risk Factors
4.
Hum Reprod ; 25(9): 2354-9, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20659911

ABSTRACT

BACKGROUND: The intrauterine environment may have a lifelong impact on individuals' health. However, results on the relationship between birth size and gonadal function are conflicting, and it remains unknown whether reproductive function is altered in adults born small for gestational age (SGA). The aim of the present study was to compare the fertility of young adults from the general population, born either SGA or appropriate for gestational age (AGA). METHODS: There were 579 adults born SGA (birthweight under the 10th percentile) who were compared with 703 subjects of the same age (age 29.4 +/- 4.1 years) born AGA (birthweight between 25th and 75th percentiles). They fulfilled a questionnaire focusing on the first attempt to give birth, to have a measure of the time to pregnancy and an estimation of the fecundability (the monthly pregnancy probability), two relevant indicators of fertility at the couple level. Ratios of fecundability between AGA and SGA subjects were adjusted for known fertility factors (age, smoking, reproductive history) and for socioeconomic status. RESULTS: Time to pregnancy was comparable in the two groups: 5.7 +/- 8.0 versus 6.6 +/- 10.5 months in AGA and SGA, respectively (P = 0.31), in women and 5.1 +/- 7 versus 6.0 +/- 9 months in AGA and SGA, respectively, in men (P = 0.53). The adjusted ratios of fecundability comparing SGA to AGA subjects were not significant: HR = 0.91 [0.68;1.21] (P = 0.5) in women and HR = 0.95 [0.67;1.74] (P = 0.82) in men. CONCLUSION: When studied in young adults from the general population, fertility is not reduced in those born SGA.


Subject(s)
Fertility , Infant, Small for Gestational Age , Adult , Birth Rate , Birth Weight , Cohort Studies , Female , Humans , Infant, Newborn , Infertility/epidemiology , Male , Registries , Surveys and Questionnaires , Time Factors
5.
Int J Infect Dis ; 92: 49-52, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31866549

ABSTRACT

Lassa fever (LF) is an endemic viral hemorrhagic fever in West Africa. Among the serious complications of the disease are neurological manifestations whose spectrum is incompletely known. Here we report the case of a 61-year-old man who developed a delayed-onset paraparesis a few weeks after getting infected with Lassa virus, thereby suggesting a possible association between LF and spinal cord disorders.


Subject(s)
Lassa Fever/complications , Paraparesis/virology , Africa, Western , Humans , Lassa Fever/epidemiology , Lassa virus , Male , Middle Aged , Time Factors
6.
J Neurol Neurosurg Psychiatry ; 80(12): 1394-8, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19917821

ABSTRACT

Bilateral periventricular nodular heterotopia (BPNH) is the most common form of periventricular heterotopia. Mutations in FLNA, encoding filamin A, are responsible for the X linked dominant form of BPNH (FLNA-BPNH). Recently, atypical phenotypes including BPNH with Ehlers-Danlos syndrome (BPNH-EDS) have been recognised. A total of 44 FLNA mutations have so far been reported in this phenotype. Most of these mutations lead to a truncated protein, but few missense mutations have also been described. Here, the results of a mutation screening conducted in a series of 32 BPNH patients with the identification of 12 novel point mutations in 15 patients are reported. Nine mutations were truncating, while three were missense. Three additional patients with BPNH-EDS and a mutation in FLNA are described. No phenotype-genotype correlations could be established, but these clinical data sustain the importance of cardiovascular monitoring in FLNA-BPNH patients.


Subject(s)
Contractile Proteins/genetics , Microfilament Proteins/genetics , Periventricular Nodular Heterotopia/genetics , Adolescent , Adult , Child , Child, Preschool , Female , Filamins , France , Genetic Association Studies , Genotype , Humans , Male , Middle Aged , Mutation, Missense/genetics , Phenotype , Point Mutation/genetics , Young Adult
7.
Cancer Radiother ; 13(1): 1-10, 2009 Jan.
Article in French | MEDLINE | ID: mdl-19119041

ABSTRACT

PURPOSE: To study prognostic factors of obliteration and risk factors of brain radiation necrosis in order to propose an algorithm for radiosurgery prescription for cerebral arteriovenous malformations (cAVM). MATERIAL AND METHODS: One hundred and seventy-nine patients were analysed. Radiosurgery delivered 6 or 10 MV X-rays by arc therapy in 84% of cases, or by fixed field in 16% of cases using two different micro-multileaf collimators (micro-MLC). Follow-up consisted of screening radiation necrosis by MRI every 6 months, and assessing local control by arteriography every 2 years. Obliteration was defined as at least 95% reduction of cAVM volume. Cox proportional hazard model was used to evaluate the local control and the appearance of radiation necrosis over time. RESULTS: Local control rate was 82.7% with the mean follow-up of 3.1 years (0.5-11). Significant prognostic factors were: simple nidus (RR=2.8, p<0.0001), number of embolizations before radiosurgery below 4 (RR=2.9, p<0.0001), prescribed dose to the periphery of at least 18 Gy (RR=2, p=0.0002), nidus volume below8cm(3) (RR=1.9, p=0.0002), and number of table positions below six (RR=1.4, p=0.05). Radiation necrosis rate was 11.2% with a mean time to onset of 18 months. Significant predictive factors were: fixed field versus arc therapy (according to MLC RR=9.1, p<0.0001, and RR=15.1, p=0.01), age below 30 years (RR=2.5, p=0.04), depth of cAVM greater than or equal to 7 cm (RR=7.6, p=0.008), and volume of brain tissue covered by the 12 Gy isodose (V12 Gy) of at least 11 cm(3) (RR=7.8, p=0.05). CONCLUSION: A radiosurgery prescription algorithm taking into account the prescribed dose to the periphery (> or = 18 Gy) and reduction of V12 Gy was elaborated from these data.


Subject(s)
Algorithms , Brain Diseases , Intracranial Arteriovenous Malformations/surgery , Radiation Injuries , Radiosurgery , Adolescent , Adult , Aged , Analysis of Variance , Brain Diseases/diagnosis , Brain Diseases/epidemiology , Brain Diseases/etiology , Cerebral Angiography , Chi-Square Distribution , Child , Decision Trees , Dose Fractionation, Radiation , Female , Follow-Up Studies , France/epidemiology , Humans , Intracranial Arteriovenous Malformations/complications , Kaplan-Meier Estimate , Magnetic Resonance Imaging , Male , Middle Aged , Necrosis , Predictive Value of Tests , Prescriptions , Prognosis , Proportional Hazards Models , Radiation Injuries/diagnosis , Radiation Injuries/epidemiology , Radiation Injuries/etiology , Radiosurgery/adverse effects , Radiosurgery/methods , Retrospective Studies , Risk Factors , Severity of Illness Index , Treatment Outcome
8.
Rev Neurol (Paris) ; 165(10): 803-11, 2009 Oct.
Article in French | MEDLINE | ID: mdl-19150724

ABSTRACT

Diagnosis of epileptic seizure may be difficult in older patients because seizure manifestations are often unusual: confusion, paresis... and because there are multiple differential diagnoses (syncope, transient ischemic attack, transient global amnesia...). To promote and facilitate the diagnosis of seizures in the elderly, neurologists and gerontologists must work together and focus their strategy on two points: firstly, the knowledge of the specific presentation of seizures in elderly patients, and secondly, the adoption of a reasoning based on seizures and not epileptic syndromes. A multidisciplinary group worked on epilepsy of the elderly to elaborate an electro-clinical score which aims to help establish the diagnosis of epilepsy in elderly patients in different clinical settings. This electro-clinical score is based on a systematic review of scientific literature and the recommendations are explicitly linked to supporting evidence. Further, clinical validation of the electro-clinical score is required.


Subject(s)
Aged/physiology , Electroencephalography , Epilepsy/diagnosis , Seizures/diagnosis , Algorithms , Behavior , Cognition/physiology , Confusion/psychology , Epilepsy/complications , Epilepsy/psychology , Humans , Reproducibility of Results , Seizures/complications , Seizures/psychology
9.
J Vet Cardiol ; 26: 10-18, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31785529

ABSTRACT

Transcatheter pulmonary valve (TPV) implantation is a therapeutic approach approved by the United States Food and Drug Administration for human patients with failing pulmonary conduits in 2010 and for failing bioprosthetic surgical pulmonary valves in 2017. We report here the first successful transcatheter implantation of a stented valve in a pulmonary position in a dog with congenital pulmonary valve disease. A 3-year-old, 10.9 kg, client-owned Beagle dog was referred for a follow-up visit after a percutaneous balloon valvuloplasty performed 22 months before for treatment of a severe type A valvular pulmonary stenosis. The Doppler-derived peak pressure gradient was 348 mmHg before the procedure and 66 mmHg 24 h after. The dog was lethargic. Echocardiography revealed a mild pulmonary stenosis (pressure gradient-43 mmHg), severe pulmonary regurgitation, and secondary severe right ventricular and right atrial dilation. Worsening of right heart dilation was observed 2 months later despite medical therapy. A TPV implantation was performed using a prestented Melody bovine jugular bioprosthetic valve. The dog recovered uneventfully and was discharged 10 days after the procedure. Right heart dilation resolved within 15 days. The dog was doing well 7 months after valve implantation. This case demonstrates that TPV implantation with a stented valve is technically feasible in dogs with severe pulmonary valve disease. Stringent postoperative care, with particular attention to thrombosis and infectious endocarditis, and appropriate sizing and positioning of the valve stent are keys to the success of this procedure.


Subject(s)
Cardiac Catheters/veterinary , Dog Diseases/surgery , Heart Valve Prosthesis Implantation/veterinary , Heart Valve Prosthesis/veterinary , Pulmonary Valve Insufficiency/veterinary , Animals , Cardiac Catheterization/methods , Cardiac Catheterization/veterinary , Dog Diseases/diagnostic imaging , Dogs , Female , Heart Valve Prosthesis Implantation/methods , Pulmonary Valve Insufficiency/diagnostic imaging , Pulmonary Valve Insufficiency/surgery
10.
Trials ; 20(1): 616, 2019 Oct 29.
Article in English | MEDLINE | ID: mdl-31665085

ABSTRACT

BACKGROUND: Investigator-initiated clinical studies (IITs) are crucial to generate reliable evidence that answers questions of day-to-day clinical practice. Many challenges make IITs a complex endeavour, for example, IITs often need to be multinational in order to recruit a sufficient number of patients. Recent studies highlighted that well-trained study personnel are a major factor to conduct such complex IITs successfully. As of today, however, no overview of the European training activities, requirements and career options for clinical study personnel exists. METHODS: To fill this knowledge gap, a survey was performed in all 11 member and observer countries of the European Clinical Research Infrastructure Network (ECRIN), using a standardised questionnaire. Three rounds of data collection were performed to maximize completeness and comparability of the received answers. The survey aimed to describe the landscape of academic training opportunities, to facilitate the exchange of expertise and experience among countries and to identify new fields of action. RESULTS: The survey found that training for Good Clinical Practice (GCP) and investigator training is offered in all but one country. A specific training for study nurses or study coordinators is also either provided or planned in ten out of eleven countries. A majority of countries train in monitoring and clinical pharmacovigilance and offer specific training for principal investigators but only few countries also train operators of clinical research organisations (CRO) or provide training for methodology and quality management systems (QMS). Minimal requirements for study-specific functions cover GCP in ten countries. Only three countries issued no requirements or recommendations regarding the continuous training of study personnel. Yet, only four countries developed a national strategy for training in clinical research and the career options for clinical researchers are still limited in the majority of countries. CONCLUSIONS: There is a substantial and impressive investment in training and education of clinical research in the individual ECRIN countries. But so far, a systematic approach for (top-down) strategic and overarching considerations and cross-network exchange is missing. Exchange of available curricula and sets of core competencies between countries could be a starting point for improving the situation.


Subject(s)
Biomedical Research/education , Clinical Trials as Topic , Research Personnel/education , Curriculum , Europe , Humans , Pharmacology, Clinical/education , Pharmacovigilance , Surveys and Questionnaires
11.
Diabetes Metab ; 34(6 Pt 1): 601-5, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18952477

ABSTRACT

BACKGROUND: While the incidence of type 1 diabetes in children has increased in various parts of the world, in France, no actual figures have been available since 1997. OBJECTIVE: The aim of this study was to determine whether or not the pattern of increase in the incidence of type 1 diabetes in children aged less than 15 years varies with age at onset in Aquitaine (France) over a 17-year period. PATIENTS AND METHODS: From 1988 to 1997, all newly diagnosed cases of type 1 diabetes were confirmed by registration into the French Registry of Incidence of Diabetes. Subsequently, all cases registered from 1998 to 2004 were collected within paediatric centres in Aquitaine as part of their hospital-based prospective records. RESULTS: In the overall population, the age- and gender-adjusted incidence rate increased from 8.86 per 100,000 per year (95% CI: 6.27-11.45) in 1988 to 13.47 per 100,000 per year (95% CI: 10.29-16.65) in 2004, indicating an annual increase in incidence of 3.34% (95% CI: 3.33-3.34). Median age at diabetes onset for cases in the first registration period (1988-1996) was significantly higher than that in the second registration period (1997-2004): 10.04 years (range: 6.64-12.53) versus 8.83 years (range: 5.48-11.73), respectively (P=0.01). The annual increase in incidence rate was highest in the youngest children and varied significantly with age (0-4 years: 7.59%; 5-9 years: 4.06%; 10-14 years: 1.28%). CONCLUSION: These results indicate a doubling of the incidence of type 1 diabetes in children every 30 years in Aquitaine, with an even steeper increase among younger children, thus underscoring the need for appropriate adaptation of the system of healthcare provision.


Subject(s)
Diabetes Mellitus, Type 1/epidemiology , Adolescent , Child , Child, Preschool , Female , France/epidemiology , Humans , Incidence , Infant , Male , Time Factors
12.
Cancer Radiother ; 12(6-7): 571-6, 2008 Nov.
Article in French | MEDLINE | ID: mdl-18703372

ABSTRACT

Ductal carcinoma in situ is defined as breast cancer confined to the ducts of the breast without evidence of penetration of the basement membrane. Local treatment quality represents one of the most prognostic factors as half of recurrences are invasive diseases. The main goal of adjuvant radiotherapy after conservative surgery is to decrease local recurrences and to permit breast conservation with low treatment-induced sequelae. Several randomized trials have established the impact of 50 Gy to the whole breast in terms of local control. Nevertheless, no randomized trial is still available concerning the role of the boost in this disease. In this review, we present updated results of the literature and we detail the French multicentric randomized trial evaluating the impact of a 16 Gy boost after 50 Gy delivered to the whole breast in 25 fractions and 33 days. This protocol will start inclusions in October 2008.


Subject(s)
Breast Neoplasms/radiotherapy , Carcinoma, Intraductal, Noninfiltrating/radiotherapy , Breast Neoplasms/pathology , Carcinoma, Intraductal, Noninfiltrating/pathology , Female , Humans , Multicenter Studies as Topic , Necrosis , Neoplasm Invasiveness , Neoplasm Recurrence, Local/epidemiology , Prognosis , Radiotherapy Dosage , Randomized Controlled Trials as Topic
13.
Neurochirurgie ; 54(3): 484-98, 2008 May.
Article in French | MEDLINE | ID: mdl-18440571

ABSTRACT

PURPOSE: To compare resective surgery and medical therapy in a cost-effectiveness analysis in a multicenter cohort of adult patients with partial intractable epilepsy. POPULATION AND METHODS: Adult patients with partial, medically intractable, potentially operable epilepsy were eligible and followed every year over five years. Effectiveness was defined as one year without seizure. The long-term costs and effectiveness were extrapolated over the patients' lifetime with a Markov model. Productivity (indirect costs) and quality of life (QOLIE-31, SEALS) were also assessed. Changes before and after surgery were compared between the two groups. RESULTS: Two hundred and eighty-nine patients were included (119 with surgery, 161 medically treated, six not eligible, three lost to follow-up). One year after surgery, 81% of the patients were seizure-free; at two and three years, this rate was 78%. In the medical group, these rates were 10, 18, and 15%, respectively. The cost of the explorations was euro 8464; including surgery, it was euro 19,700. In the medical group, the average annual direct costs were between 3500 and euro 6000. At two years after surgery, the annual direct cost decreased to euro 2768, at three years, it was euro 1233, predominately antiepileptic drug costs. Surgery became cost-effective between seven and eight years. In the surgical group, all the quality-of-life scores improved at one year after surgery and were stable during the second and third years. CONCLUSION: Surgical therapy was cost-effective at the middle term even though indirect costs were not considered.


Subject(s)
Epilepsies, Partial/economics , Epilepsies, Partial/surgery , Neurosurgical Procedures/economics , Adolescent , Adult , Anticonvulsants/therapeutic use , Cohort Studies , Cost-Benefit Analysis , Drug Resistance , Efficiency , Epilepsies, Partial/psychology , Female , Follow-Up Studies , France , Humans , Male , Markov Chains , Middle Aged , Models, Economic , Postoperative Complications/epidemiology , Postoperative Complications/psychology , Quality of Life , Treatment Outcome
14.
Mol Cell Biol ; 18(1): 314-21, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9418878

ABSTRACT

Uptake of uracil by the yeast Saccharomyces cerevisiae is mediated by a specific permease encoded by the FUR4 gene. Uracil permease located at the cell surface is subject to two covalent modifications: phosphorylation and ubiquitination. The ubiquitination step is necessary prior to permease endocytosis and subsequent vacuolar degradation. Here, we demonstrate that a PEST-like sequence located within the cytoplasmic N terminus of the protein is essential for uracil permease turnover. Internalization of the transporter was reduced when some of the serines within the region were converted to alanines and severely impaired when all five serines within the region were mutated or when this region was absent. The phosphorylation and degree of ubiquitination of variant permeases were inversely correlated with the number of serines replaced by alanines. A serine-free version of this sequence was very poorly phosphorylated, and elimination of this sequence prevented ubiquitination. Thus, it appears that the serine residues in the PEST-like sequence are required for phosphorylation and ubiquitination of uracil permease. A PEST-like sequence in which the serines were replaced by glutamic acids allowed efficient permease turnover, suggesting that the PEST serines are phosphoacceptors.


Subject(s)
Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Nucleotide Transport Proteins , Saccharomyces cerevisiae Proteins , Saccharomyces cerevisiae/enzymology , Binding Sites , Enzyme Activation/genetics , Genes, Fungal , Mutation , Saccharomyces cerevisiae/genetics , Sequence Analysis
15.
Diabetes Metab ; 33(6): 453-8, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17964843

ABSTRACT

UNLABELLED: The prevalence of celiac disease is higher in children with type 1 diabetes mellitus (DM) than in the general pediatric population, but may vary widely across countries. Sensitive and specific antibody tests are available for detecting celiac disease. AIMS: To evaluate the prevalence in France of histologically documented celiac disease in a vast cohort of children with type 1 DM, and to describe the features of celiac disease and treatment response. METHODS: Retrospective cohort study of 950 children with type 1 diabetes seen between 1994 and 2001. Antibodies to gliadin, reticulin, endomysium and transglutaminase were looked for one to seven times in each patient. RESULTS: Fifteen patients (1.6%) had biopsy-confirmed celiac disease. Symptoms led to the diagnosis in six patients (mean age, 7 years) and screening tests in nine patients (mean age, 11 years). Anti-endomysium antibodies were consistently positive. Tests for HLA-DQB1 0201 and/or 0302 were positive. Anti-endomysium antibody seroconversion was seen in two patients, 2 and 6 years, respectively, after the diagnosis of diabetes. In another patient, the biopsy became abnormal 6 years after the first positive anti-endomysium antibody test (latent form). After a mean of 3 years on a gluten-free diet, significant increases were noted in body weight (P=0.04) and insulin dose (P=0.05); clinical symptoms completely resolved in five of the six symptomatic patients. CONCLUSIONS: The prevalence of celiac disease is higher in children with type 1 DM than in the general pediatric population. Serological screening is useful for diagnosing asymptomatic celiac disease, detecting seroconversion and monitoring latent forms of disease.


Subject(s)
Celiac Disease/epidemiology , Diabetes Mellitus, Type 1/epidemiology , Celiac Disease/complications , Celiac Disease/physiopathology , Child , Cohort Studies , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/physiopathology , Diet , Gliadin/immunology , Glutens/adverse effects , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Paris/epidemiology , Prevalence
16.
Neurochirurgie ; 62(3): 146-50, 2016 Jun.
Article in French | MEDLINE | ID: mdl-27234916

ABSTRACT

BACKGROUND: Vagus nerve stimulation is an adjunctive palliative therapy for refractory epilepsy. MATERIAL AND METHODS: We reviewed the clinical and surgical records of patients who had a VNS implantation for intractable epilepsy between the years 1999 and 2010 at two institutions, Bordeaux and Toulouse University Hospitals. RESULTS: A total of 101 patients were included of whom 57 were male. Median age at epilepsy onset was 7.5 years, inter quartile range (IQR) [2.5-12.5] and the median time between epilepsy onset and VNS implantation was 21.1 years, IQR [11.9-29.5]. At the end of the study, 85 patients were alive with a functional VNS. Survival probability of having a functional VNS at 1, 2 and 5 years were respectively: 99%, IC95% [97.1,100]; 96.49%, IC95% [92.7,100] and, 88.2%, IC95% [79.9,97.4]. Among the patients, 41.6% demonstrated a seizure decrease of more than 50%. The mean number of seizures was reduced by 5.7 per week. We failed to demonstrate any factor affecting the outcome. CONCLUSION: The VNS can decrease the seizure frequency but, also reduce their intensity and had a favourable effect on the patients mood. Morbidity is low and the therapeutic effect of the stimulation is sustainable. The indication of the VNS should be discussed earlier in the evolution of a nonsurgical and severe epilepsy.


Subject(s)
Drug Resistant Epilepsy/therapy , Vagus Nerve Stimulation , Adolescent , Adult , Anticonvulsants/therapeutic use , Combined Modality Therapy , Cross-Sectional Studies , Drug Resistant Epilepsy/drug therapy , Drug Resistant Epilepsy/psychology , Female , Humans , Male , Patient Satisfaction , Quality of Life , Retrospective Studies , Treatment Outcome , Young Adult
17.
J Clin Endocrinol Metab ; 90(10): 5672-6, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16030157

ABSTRACT

CONTEXT: Implication of the IGF-IGF-binding protein (IGFBP) axis in the development of metabolic and cardiovascular diseases has been well documented. It has also been shown that an adverse intrauterine environment alters the IGF-IGFBP axis during childhood. OBJECTIVE: The objective of this study was to investigate whether these alterations persist into adulthood. DESIGN AND METHODS: Fasting serum IGF-I, IGFBP-3, and insulin concentrations were measured, and their determinants were analyzed in a cohort of young adult subjects (22 yr of age) born either small (SGA; n = 461) or appropriate (AGA; n = 568) for gestational age. RESULTS: In adulthood, subjects born SGA had significantly lower mean serum IGF-I (320 +/- 137 vs. 348 +/- 143 microg/liter; P = 0.0015), IGFBP-3 (4700 +/- 700 vs. 4800 +/- 800 microg/liter; P = 0.04), and IGF-I/IGFBP-3 ratio (0.067 +/- 0.026 vs. 0.072 +/- 0.025; P = 0.01) than those born AGA. The fasting IGF-I concentration and the IGF-I/IGFBP-3 ratio were significantly inversely associated with age, body mass index, smoking, and oral contraception and were positively related to birth weight and fasting insulin levels. The IGFBP-3 concentration was significantly negatively correlated to age and smoking and was positively related to insulin concentration and oral contraception. After adjustment for age, height, body mass index, gender, smoking, and oral contraception, the mean IGF-I concentration and the mean IGF-I/IGFBP-3 ratio remained significantly lower in the SGA compared with the AGA group (P = 0.003 and P = 0.01, respectively). CONCLUSIONS: Serum IGF-I concentrations and the IGF-I/IGFBP-3 ratio are lower in adult subjects born SGA. Although the origin of this persisting alteration of the IGF-IGFBP axis in adulthood needs to be elucidated, its potential contribution to the long-term metabolic and cardiovascular complications associated with fetal growth restriction is important to consider in the future.


Subject(s)
Infant, Small for Gestational Age/metabolism , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor I/metabolism , Adult , Anthropometry , Birth Weight/physiology , Body Height/physiology , Case-Control Studies , Cohort Studies , Female , Growth/physiology , Humans , Infant, Newborn , Linear Models , Male , Regression Analysis
18.
Diabetes ; 44(9): 1029-32, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7657024

ABSTRACT

Islet cell antibodies (ICAs) are predictive markers of the disease in first-degree relatives of patients with insulin-dependent diabetes mellitus (IDDM). The large majority of newly diagnosed cases, however, will develop in children with no family history of diabetes. In France, the risk for development of IDDM up to the age of 20 years is 60 times higher in first-degree relatives than in the general population. The aim of this study was to test whether data collected in the first-degree relatives of IDDM patients could be transferred to children for the prediction of overt diabetes. A large population-based cohort of French school-aged children (n = 13,380; ages 6-17 years) were screened for ICAs, and results were compared with those of 1,185 first-degree relatives of IDDM patients. ICA prevalence rates were significantly different in the two populations (5.5% vs. 1.5%; P < 0.0001), with a significantly higher proportion of high ICA titers in first-degree relatives (37%) than in schoolchildren (14%) (P = 0.0005). ICA titers remained remarkably stable in children over 4 years. Insulin autoantibodies (IAAs) were found in 3.4 and 15.4% of ICA+ children and first-degree relatives, respectively. Susceptibility alleles at the human leukocyte antigen (HLA)-DQB1 locus were observed significantly more frequently in children in whom ICA titers > or = 20 Juvenile Diabetes Foundation units (JDF U) were found on two separate occasions (67%) than in ICA- children (52%) (P = 0.05). Five subjects developed overt diabetes during follow-up. ICA titers of > 20 JDF U were found in all of them on the first sample and at follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Autoantibodies/blood , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , HLA-DQ Antigens/genetics , Adolescent , Adult , Age Factors , Alleles , Child , Child, Preschool , Diabetes Mellitus, Type 1/epidemiology , Family , Female , France , HLA-DQ Antigens/blood , HLA-DQ beta-Chains , Histocompatibility Testing , Humans , Immunogenetics/methods , Islets of Langerhans/immunology , Male , Middle Aged
19.
Diabetes ; 47(3): 470-5, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9519756

ABSTRACT

In utero growth retardation has been linked to a reduced rate of cell division in the fetal organs that undergo rapid growth and to permanent changes and adaptations (programming) that may affect the physiology in adult life. In particular, in utero growth retardation as reflected by a low birth weight for gestational age has been shown to be associated with a relative insulin resistance in adults. How programming may influence glucose metabolism is not completely understood, and the possible role of genetic factors has not been explored. The angiotensin I-converting enzyme gene insertion/deletion (ACE I/D) polymorphism may predispose to insulin resistance and modulate the expression of several common cardiovascular and renal disorders, especially in people with diabetes. The possible impact of this polymorphism on plasma glucose and insulin levels was investigated in a group of young adults born at term whose length or weight at birth were in the lowest 3% of the sex and gestational age-adjusted distribution (SGA, n = 172) and a group of control individuals born with an appropriate birth weight for gestational age (AGA, n = 207). In this study, we have previously demonstrated an association between SGA and relative insulin resistance, especially in those with shorter gestational age. In the SGA group, fasting plasma glucose and insulin levels were significantly correlated (R = 0.196, P < 0.015), with this association being significant only in ACE II individuals (R = 0.539, P < 0.0009). In the AGA group, fasting plasma glucose and insulin levels were not significantly correlated. Consistent with this observation, the relationship between the ACE polymorphism and the insulin response to a glucose load was significantly heterogeneous between the AGA and SGA groups (P < 0.05); this was due to a tendency for ACE II individuals in the SGA group to exhibit increased 30-min plasma insulin levels (P < 0.05). In the SGA group, there was a significant interaction between gestational age and genotype on the insulin area (P < 0.0004); this index was inversely associated with gestational age in ACE II (P < 0.0005) and ACE ID (P < 0.005) subjects, but not in DD homozygotes (P > 0.05). The ACE D allele may thus attenuate the additive consequences of SGA and relatively short duration of gestation on insulin resistance in young adults.


Subject(s)
Fetal Growth Retardation/genetics , Infant, Small for Gestational Age/physiology , Insulin/blood , Peptidyl-Dipeptidase A/genetics , Polymorphism, Genetic/genetics , Adult , Blood Glucose/analysis , Cohort Studies , Female , Fetal Growth Retardation/blood , Follow-Up Studies , Genotype , Gestational Age , Glucose Tolerance Test , Humans , Infant, Small for Gestational Age/blood , Insulin/metabolism , Insulin Resistance/genetics , Male , Prospective Studies , Single-Blind Method
20.
Clin Cancer Res ; 6(8): 3327-33, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10955820

ABSTRACT

The lack of new highly efficacious drugs for cancer treatment promotes the search for innovative therapeutic modalities. The authors reported the results leading to the definition of parameters needed to demonstrate a possible radiopotentiation by topotecan (TPT) on two representative human rhabdomyosarcomas (RMSs) xenografted into nude mice. Experimental studies of radiopotentiation with different doses of topotecan showed that concomitant association of topotecan and RT for 5 consecutive days provided a synergistic therapeutic effect. Response rates were statistically higher with the radiochemotherapeutic combination (P < 0.001). Efficacy enhancement factors of this combination compared with the sum of the antitumoral activity of these treatments separately administrated were 1.54 and 1.60, respectively, on both rhabdomyosarcomas. Moreover, the efficiency of the combination of radiotherapy at the dose of 20 Gy with topotecan (12.5 mg/kg) was not statistically different from that of radiotherapy at the dose of 40 Gy. According to microscopy results, the analyses performed at different periods after topotecan treatment alone, radiotherapy alone, and their combination seemed to show that tumoral repopulation by malignant cells is as fast as the dose of radiotherapy and/or topotecan is low. Furthermore, lesions observed with the dose of 40 Gy were similar to those obtained with the association of topotecan at the dose of 12.5 mg/kg and radiotherapy at the dose of 20 Gy. In conclusion, all clinical and pathological results are consistent with a radiopotentiation effect of topotecan on the two xenografted human rhabdomyosarcomas and are currently leading to the design of clinical studies.


Subject(s)
Antineoplastic Agents/pharmacology , Radiation-Sensitizing Agents/pharmacology , Rhabdomyosarcoma/radiotherapy , Topotecan/pharmacology , Adolescent , Aged , Aged, 80 and over , Animals , Combined Modality Therapy , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drug Synergism , Female , Humans , Mice , Mice, Nude , Rhabdomyosarcoma/drug therapy , Rhabdomyosarcoma/pathology , Topotecan/toxicity , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL